ATP, an attractive target for the treatment of refractory chronic cough

Zhang, Mengru; Sykes, Dominic L.; Sadofsky, Laura R.; Morice, Alyn H.

Abstract

Chronic cough is the most common complaint in respiratory clinics. Most of them have identifiable causes and some may respond to common disease-modifying therapies. However, there are many patients whose cough lacks effective aetiologically targeted treatments or remains unexplained after thorough assessments, which have been described as refractory chronic cough. Current treatments for refractory chronic cough are limited and often accompanied by intolerable side effects such as sedation. In recent years, various in-depth researches into the pathogenesis of chronic cough have led to an explosion in the development of drugs for the treatment of refractory chronic cough. There has been considerable progress in the underlying mechanisms of chronic cough targeting ATP, and ongoing or completed clinical studies have confirmed the promising antitussive efficacy of P2X3 antagonists for refractory cough. Herein, we review the foundation on which ATP target was developed as potential antitussive medications and provide an update on current clinical progresses.

Citation

Zhang, M., Sykes, D. L., Sadofsky, L. R., & Morice, A. H. (2022). ATP, an attractive target for the treatment of refractory chronic cough. Purinergic Signalling, 18, 289-305. https://doi.org/10.1007/s11302-022-09877-z

• Journal Article Type: Review
• Acceptance Date: Jun 8, 2022
• Online Publication Date: Jun 21, 2022
• Publication Date: 2022-09
• Deposit Date: Oct 19, 2022
• Publicly Available Date: Oct 20, 2022
• Journal: Purinergic Signalling
• Print ISSN: 1573-9538
• Electronic ISSN: 1573-9546
• Publisher: Springer
• Peer Reviewed: Peer Reviewed
• Volume: 18
• Pages: 289-305
• DOI: https://doi.org/10.1007/s11302-022-09877-z
• Keywords: Refractory chronic cough; Cough hypersensitivity; ATP; P2X3 antagonists; Gefapixant; Antitussive
• Public URL: https://hull-repository.worktribe.com/output/4029459